{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:03:38Z","timestamp":1761102218729},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Public Health"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00038-016-0821-0","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T07:11:12Z","timestamp":1461309072000},"page":"683-692","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel"],"prefix":"10.1007","volume":"61","author":[{"given":"Gary M.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Stein-Zamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","volume":"29","author":"R Arnold","year":"2011","unstructured":"Arnold R, Galloway Y, McNicholas A, O\u2019Hallahan J (2011) Effectiveness of a vaccination program for an epidemic of meningococcal B in New Zealand. Vaccine 29:7100\u20137106","journal-title":"Vaccine"},{"key":"821_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s15010-013-0439-6","volume":"41","author":"S Ben-Shimol","year":"2012","unstructured":"Ben-Shimol S, Dagan R, Schonmann Y et al (2012) Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989\u20132010). Infection 41:791\u2013798. doi:\n                    10.1007\/s15010-013-0439-6","journal-title":"Infection"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","volume":"32","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, For the members of the Canadian immunization Monitoring Program Active (IMPACT) (2013) The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 32:e20\u2013e25. doi:\n                    10.1097\/INF.0b013e3182706b89","journal-title":"Pediatr Infect Dis J"},{"key":"821_CR4","doi-asserted-by":"publisher","unstructured":"Brouwer MC, McIntyre P, Prasad K, van de Beek D (2013) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 6:CD004405. doi:\n                    10.1002\/14651858.CD004405.pub4\n                    \n                  . Accessed 21 Jan 2015","DOI":"10.1002\/14651858.CD004405.pub4"},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/archpedi.162.11.1036","volume":"162","author":"CMP Buysse","year":"2008","unstructured":"Buysse CMP, Raat H, Hazelet JA et al (2008) Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med 162:1036\u20131041","journal-title":"Arch Pediatr Adolesc Med"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/adc.2007.131862","volume":"94","author":"CM Buysse","year":"2009","unstructured":"Buysse CM, Oranje AP, Zuidema E, Hazalet JA, Hop WCJ, Diepstaten AF, Joosten KFM (2009) Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 94:381\u2013386","journal-title":"Arch Dis Child"},{"key":"821_CR7","doi-asserted-by":"publisher","unstructured":"Buysse CMP, Vermunt LCAC, Raat H, Hazalet JA, Hop WCJ, Utens EMWJ, Joosten KFM (2010) Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect of health-related quality of life. Crit Care 14:R124. doi:\n                    10.1186\/cc9087\n                    \n                   \n                           (Published Online 29 June 2010)","DOI":"10.1186\/cc9087"},{"key":"821_CR8","volume-title":"Annual Statistical Abstract 2015","author":"Central Bureau of Statistics","year":"2015","unstructured":"Central Bureau of Statistics (2015) Annual Statistical Abstract 2015. CBS, Jerusalem"},{"key":"821_CR9","first-page":"1","volume":"54","author":"Centres for Disease Control and Prevention","year":"2005","unstructured":"Centres for Disease Control and Prevention (2005) Prevention and control of meningococcal disease recommendations of the advisory committee on immunization practices (ACIP). MMWR 54:1\u201321","journal-title":"MMWR"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/INF.0b013e3181ef25f7","volume":"30","author":"A Chandran","year":"2011","unstructured":"Chandran A, Herbert H, Misurski D, Santashan M (2011) Long-term sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 30:3\u20136","journal-title":"Pediatr Infect Dis J"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10:853\u2013861","journal-title":"Lancet Infect Dis"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","volume":"31","author":"H Christensen","year":"2013","unstructured":"Christensen H, Hickman M, Edmunds WJ, Trotter CL (2013) Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 31:2638\u20132646","journal-title":"Vaccine"},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"g5725","DOI":"10.1136\/bmj.g5725","volume":"349","author":"H Christensen","year":"2014","unstructured":"Christensen H, Trotter CL, Hickman M, Edmunds WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexero) in England: modelling study. BMJ 349:g5725","journal-title":"BMJ"},{"issue":"7","key":"821_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/INF.0b013e31820e8638","volume":"30","author":"P De Wals","year":"2011","unstructured":"De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G (2011) Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 30(7):566\u2013569. doi:\n                    10.1097\/INF.0b013e31820e8638","journal-title":"Pediatr Infect Dis J"},{"key":"821_CR15","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1016\/j.vaccine.2013.06.080","volume":"31","author":"V Delbos","year":"2013","unstructured":"Delbos V, Lem\u00e9e L, B\u00e9nichou J et al (2013) Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 31:4416\u20134420","journal-title":"Vaccine"},{"key":"821_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","volume":"12","author":"S Dellicour","year":"2007","unstructured":"Dellicour S, Greenwood B (2007) Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 12:1409\u20131421","journal-title":"Trop Med Int Health"},{"key":"821_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I (2010) Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 10:317\u2013332","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"821_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0022-3476(81)80250-8","volume":"99","author":"MS Edwards","year":"1981","unstructured":"Edwards MS, Baker CJ (1981) Complications and sequelae of meningococcal infections in children. J Pediat 99(4):540\u2013545","journal-title":"J Pediat"},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1086\/520303","volume":"26","author":"L Erickson","year":"1998","unstructured":"Erickson L, De Wals P (1998) Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994. Clin Infect Dis 26:1159\u20131164","journal-title":"Clin Infect Dis"},{"key":"821_CR20","unstructured":"FDA News Release (2014) First vaccine approved by FDA to prevent serogroup B Meningococcal disease. \n                    http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm420998.html.\n                    \n                   Accessed 1 Jan 2015"},{"key":"821_CR21","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","volume":"31","author":"G Frosi","year":"2013","unstructured":"Frosi G, Biolchi A, Sapio ML et al (2013) Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31:4968\u20134974","journal-title":"Vaccine"},{"key":"821_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1473-3099(13)70037-9","volume":"5","author":"C Gill","year":"2013","unstructured":"Gill C (2013) Novel assessment of a novel meningitis B vaccine. Lancet Infect Dis 5:381\u2013382. doi:\n                    10.1016\/S1473-3099(13)70037-9\n                    \n                   \n                           (Epub 2013 Feb 13)","journal-title":"Lancet Infect Dis"},{"key":"821_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.resuscitation.2014.10.024","volume":"86","author":"GM Ginsberg","year":"2015","unstructured":"Ginsberg GM, Kark J, Einav S (2015) Cost utility analysis of cardiac resuscitation services in Jerusalem. Resuscitation 86:54\u201361","journal-title":"Resuscitation"},{"key":"821_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4161\/hv.18500","volume":"8","author":"AR Gorringe","year":"2012","unstructured":"Gorringe AR, Pajon R (2012) Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccines Immunother 8:174\u2013183","journal-title":"Hum Vaccines Immunother"},{"issue":"6","key":"821_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu LM, European MenB Vaccine Study Group et al (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307(6):573\u2013582","journal-title":"JAMA"},{"key":"821_CR26","unstructured":"Hakin B, Cosford P (2015) Introduction of Men B immunisation for infants. Public Health England, NHS Gateway Number: 03517. \n                    https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/437906\/150622_MenB_bipartite_letter.pdf"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1086\/340050","volume":"34","author":"CM Healy","year":"2002","unstructured":"Healy CM, Butler KM, Smith EO et al (2002) Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995\u20132000. Clin Infect Dis 34:1323\u20131330","journal-title":"Clin Infect Dis"},{"key":"821_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","author":"J Holst","year":"2003","unstructured":"Holst J, Feiring B, Fuglesang JE, H\u00f8iby EA, N\u00f8kleby H, Aaberge IS, Rosenqvist E (2003) Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitis serogroup B disease. Vaccine 21:734\u2013737","journal-title":"Vaccine"},{"key":"821_CR29","unstructured":"Huels J, Wassil J, Bonefeld L, Watson P (2013) Sensitivity analysis of a model used to predict the cost effectiveness of bexero for immunisation against meningococcal disease in the United Kingdom. In: Poster presented at meningitis and septacemia in children and adults, 5\u20136 November 2013, London"},{"key":"821_CR30","unstructured":"Israel Center for Disease Control (2012) Notifiable infectious diseases in Israel, 60\u00a0years of surveillance 1951\u20132010. Publication No. 342"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/21645515.2015.1010885","volume":"11","author":"G Izuierdo","year":"2015","unstructured":"Izuierdo G, Torres JP, Santolya ME, Valenzuela MT, Vega J, Chomali M (2015) Cost-effectiveness analysis of a multicomponent meningococcal serogroup B (4CMeb B) vaccine in epidemic situation in a middle-income country. Hum Vaccine Immunother 11:875\u2013883. doi:\n                    10.1080\/21645515.2015.1010885","journal-title":"Hum Vaccine Immunother"},{"key":"821_CR32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/00003246-199011000-00020","volume":"18","author":"P Jacobs","year":"1990","unstructured":"Jacobs P, Noseworthy TW (1990) National estimates of intensive care utilization and costs. Crit Care Med 18:1282\u20131286","journal-title":"Crit Care Med"},{"key":"821_CR33","unstructured":"JCVI (2014) JCVI position statement on use of bexsero meningococcal B vaccine in the UK. 2014. \n                    https:\/\/www.gov.uk\/government\/publications\/meningococcal-b-vaccine-jcvi-position-statement\n                    \n                  . Accessed 21 Aug 2014"},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 Causes of Death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095\u20132128","journal-title":"Lancet"},{"key":"821_CR35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4161\/hv.3.5.4458","volume":"3","author":"A McNicholas","year":"2007","unstructured":"McNicholas A, Galloway Y, Stehr-Green P et al (2007) Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004\u20132006. Hum Vaccines 3:196\u2013204","journal-title":"Hum Vaccines"},{"key":"821_CR36","unstructured":"Meningococcal B Pilot Project Task Group (2014). The recommended use of the multicomponent meningococcal B (4CMENB) vaccine in Canada: common guidance statement. Ottawa"},{"key":"821_CR37","unstructured":"Ministry of Health (2012) Ambulatory and hospitalization price data July 1st 2012. \n                    http:\/\/www.health.gov.il\/subjects\/finance\/taarifon\/pages\/pricelist.aspx\n                    \n                  . Accessed 11 July 2013"},{"key":"821_CR38","unstructured":"Novartis Media release (2012) Novartis receives positive CHMP opinion for Bexsero\u00ae, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe. \n                    http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1658747.shtml\n                    \n                  . Accessed 15 May 2013"},{"key":"821_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/hv.23888","volume":"9","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Hak E, van der Ende A, Christenden H, van der Dobbelstein GP, Postma MJ (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Hum Vaccines Immunother 9:1\u201310","journal-title":"Hum Vaccines Immunother"},{"key":"821_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365\u2013366","journal-title":"BMJ"},{"key":"821_CR42","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DRI et al (2014) Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384:2123\u20132131","journal-title":"Lancet"},{"key":"821_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1017\/S0950268800057472","volume":"112","author":"RJ Scholten","year":"1994","unstructured":"Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J (1994) Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 112:115\u2013124","journal-title":"Epidemiol Infect"},{"key":"821_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0749-3797(02)00462-2","volume":"23","author":"RD Scott","year":"2002","unstructured":"Scott RD, Meltzer MI, Erikson LJ, DeWals P, Rosenstein NE (2002) Vaccinating first-year college students living in dormitories for meningococcal disease. Am J Prev Med 23:98\u2013105","journal-title":"Am J Prev Med"},{"key":"821_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/01.PCC.0000163285.74452.23","volume":"6","author":"R Slack","year":"2005","unstructured":"Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA (2005) Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med 6:477\u2013479","journal-title":"Pediatr Crit Care Med"},{"key":"821_CR48","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","volume":"15","author":"S Sridhar","year":"2015","unstructured":"Sridhar S, Greenwood B, Head C et al (2015) Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis 15:1334\u20131346. doi:\n                    10.1016\/S1473-3099(15)00217-0\n                    \n                   \n                           (Epub 2015 Oct 6)","journal-title":"Lancet Infect Dis"},{"key":"821_CR49","first-page":"82","volume":"136","author":"C Stein-Zamir","year":"2008","unstructured":"Stein-Zamir C, Abramson N, Zentner G, Sloob H, Valinsky L, Block C (2008) Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect 136:82\u201389","journal-title":"Epidemiol Infect"},{"key":"821_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/INF.0000000000000282","volume":"33","author":"C Stein-Zamir","year":"2014","unstructured":"Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D (2014) The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J 33:777\u2013779","journal-title":"Pediatr Infect Dis J"},{"key":"821_CR51","doi-asserted-by":"publisher","first-page":"e0123383","DOI":"10.1371\/journal.pone.0123383","volume":"10","author":"M Tirani","year":"2015","unstructured":"Tirani M, Meregaglia M, Melegaro A (2015) Health and economic outcomes of introducing the new Men B vaccine (bexero) into the Italian routine infant immunisation programme. PLoS One 10:e0123383. doi:\n                    10.1371\/journal.pone.0123383","journal-title":"PLoS One"},{"key":"821_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0272989X05284109","volume":"26","author":"CL Trotter","year":"2006","unstructured":"Trotter CL, Edmunds WJ (2006) Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Mak 26:38\u201347","journal-title":"Med Decis Mak"},{"key":"821_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","author":"CL Trotter","year":"2004","unstructured":"Trotter CL, Andrews NJ, Zaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4\u00a0years after introduction. Lancet 364:365\u2013367","journal-title":"Lancet"},{"key":"821_CR54","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","volume":"32","author":"HA Tu","year":"2014","unstructured":"Tu HA, Deeks SL, Morris SK et al (2014) Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 32:5436\u20135446","journal-title":"Vaccine"},{"key":"821_CR55","doi-asserted-by":"crossref","unstructured":"Vesikari T, Eposito S, Ypma E et al (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMEN B) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet 381:825\u201335 (Erratum in: Lancet (2013) 381: 804)","DOI":"10.1016\/S0140-6736(12)61961-8"},{"key":"821_CR56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RE Viner","year":"2012","unstructured":"Viner RE, Booy R, Johnson H et al (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11:774\u2013783","journal-title":"Lancet Neurol"},{"key":"821_CR57","first-page":"2001","volume-title":"Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health","author":"WHO Commission on MacroEconomics and Health","year":"2001","unstructured":"WHO Commission on MacroEconomics and Health (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, p 2001"},{"key":"821_CR58","doi-asserted-by":"publisher","first-page":"g2327","DOI":"10.1136\/bmj.g2327","volume":"348","author":"J Wise","year":"2014","unstructured":"Wise J (2014) News: meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness. BMJ 348:g2327. doi:\n                    10.1136\/bmj.g2327","journal-title":"BMJ"},{"key":"821_CR59","unstructured":"World Health Organization (1996) Murray CJL, Lopez AD (eds) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. WHO, USA"},{"key":"821_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","volume":"15","author":"C Wright","year":"2013","unstructured":"Wright C, Wordsworth R, Glennie L (2013) Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs 15:49\u201358","journal-title":"Paediatr Drugs"}],"container-title":["International Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00038-016-0821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00038-016-0821-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00038-016-0821-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00038-016-0821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T13:52:29Z","timestamp":1589809949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00038-016-0821-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s00038-016-0821-0","relation":{},"ISSN":["1661-8556","1661-8564"],"issn-type":[{"value":"1661-8556","type":"print"},{"value":"1661-8564","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]},"assertion":[{"value":"18 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study did not receive any funds and was carried out by salaried staff members of their respective institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}